Caladrius unveils positive results of CLBS16 in CMD treatment
Category: #health  By Pankaj Singh  Date: 2019-11-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Caladrius unveils positive results of CLBS16 in CMD treatment
  • The data shows a major statistical improvement in coronary flow reserve
     
  • Single-use CLBS16 can reportedly improve heart function and symptoms

Caladrius Biosciences, Inc., a biopharmaceutical firm mainly focused on the development of the treatments for certain cardiovascular diseases, with the help of researchers from Mayo Clinic in Rochester, Minnesota, the Christ Hospital in Cincinnati and Los Angeles’ Cedars-Sinai, recently presented results from the autologous CD34+ cell therapy, also known as CLBS16, of Caladrius’s ESCaPE-CMD trial, at the American Heart Association Scientific Sessions 2019.

The results presented were for patients who have finished the six-month follow-up date while the remaining results from the other patients will be presented by the end of 2019. The data depicted a major statistical improvement in the coronary flow reserve in relation to symptom relief in patients suffering from coronary microvascular dysfunction after they were injected with CLBS16 intracoronary injection.

Caladrius’ CEO and President, David J. Mazzo, Ph.D. stated that CLB16 represents a probable breakthrough for CMD treatment, a condition that millions suffer from in the U.S. and has an excessive effect on women. The trial is the first time when therapy has exhibited its capability of increasing coronary flow reserve and possibly reverse CMD after one dose.

Apparently, the ESCaPE-CMD trial is essentially an interventional study intended to analyze the effect of autologous CD34+ cell therapy (CLBS16) of Caladrius on the symptoms as well as indicators of CDM while also being able to analyze the tolerance for the treatment. The trial had reportedly finished the enrollment of 20 patients targeted in May 2019. Every patient was given a single infusion of GCSF-mobilized CD34+ cells which were formulated as CLBS16.

Chief Medical officer, Caladrius, Douglas W. Losordo, M.D., FACC, FAHA, commented that patients suffering from CMD tend to be frustrated and in despair often due to unresolved symptoms after they have exhausted every therapy. The data indicate that CD34+ repair cells will be able to provide strong improvements in the symptoms and reduce any risks of dangerous cardiovascular outcomes.

 

Source Credits- https://www.caladrius.com/press-release/caladrius-biosciences-reports-positive-results-for-clbs16-from-the-escape-cmd-trial-at-american-heart-association-scientific-sessions-2019/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Bettervest invests in Oakridge Rooftops to support solar projects
Bettervest invests in Oakridge Rooftops to support solar projects
By Pankaj Singh

Oakridge Rooftops Pvt. Ltd., a solar energy company based in India, has reportedly secured funding from Germany-based crowdfunding platform, Bettervest Gmbh. The solar firm has raised the funding for urban solar projects in New Delhi. Oakridge CEO, ...

Databricks buys 8080 Labs to boost its low code/no code offerings
Databricks buys 8080 Labs to boost its low code/no code offerings
By Pankaj Singh

California-based enterprise software company- Databricks has acquired German software startup 8080 Labs that developed bamboolib- a leading GUI for the Python-based Pandas data analysis and manipulation system. The purchase of 8080 Labs makes the fi...

Google rolls out GNI Advertising Lab for news publishers in India
Google rolls out GNI Advertising Lab for news publishers in India
By Pankaj Singh

American tech giant, Google LLC has recently announced the launch of Google News Initiative (GNI) Advertising Lab program for supporting small and medium-sized news publishers that generate original and accurate news for regional and local communitie...